Abstract 2590
Background
Pazopanib is a standard first line treatment for metastatic clear cell renal cell carcinoma (RCC). Very few data on its activity in non-clear cell RCC (nccRCC) are currently available in the literature. We retrospectively analyzed efficacy and toxicity of Pazopanib in an Italian multicenter cohort of nccRCC patients.
Methods
Records from nccRCC patients treated with first line Pazopanib were reviewed and collected. Response rate (RR), progression free survival (PFS), and overall survival (OS) were evaluated in this cohort. Univariate analysis were conducted to correlate clinicopathological factors with outcome. Descriptive analysis of patients and diseases characteristics were also performed.
Results
Between 2010 and 2015, 37 patients with nccRCC were treated with Pazopanib as first line therapy at 17 Italian centers. 24% had chromophobe histology, 51% papillary, 22% unclassified and 3% had Xp11 translocation. Motzer and Heng risk were good in 22% and 24%, intermediate in 68% and 49% and poor in 10% and 22% of patients respectively. 76% had nephrectomy. 57% had ECOG performance status (PS) = 0, 27% PS = 1 and 16% PS = 2-3. 22% had a basal neutrophil to lymphocyte ratio (NLR) ≥ 3. Dose reductions/interruptions of Pazopanib for toxicity were required in 46% of cases; G3-4 toxicity occurred in 32% of patients, G1-2 in 89%. 81% achieved clinical benefit (partial response or stable disease), while 16% had disease progression as best response. Median PFS (38% censored) and OS (46% censored) were 15.9 [95%CI 5.9–25.8] and 17.3 [95%CI 11.5-23.0] months, respectively. At the univariate analysis, factors associated with PFS were nephrectomy (p = 0.02), Motzer score (p
Conclusions
In nccRCC patients, treatment with Pazopanib demonstrated to be effective and feasible, despite dose reductions often required for toxicity in this population.
Clinical trial identification
not applicable
Legal entity responsible for the study
Santa Chiara Hospital, Trento.
Funding
N/A
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract